BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Liu H, Zhu Z, Qi X, Yuan W, Tian M, Wang D, Xu J. LACTB suppresses migration and invasion of glioblastoma via downregulating RHOC/Cofilin signaling pathway. Biochem Biophys Res Commun 2022;629:17-25. [PMID: 36088805 DOI: 10.1016/j.bbrc.2022.09.002] [Reference Citation Analysis]
2 Sanati M, Binabaj MM, Ahmadi SS, Aminyavari S, Javid H, Mollazadeh H, Bibak B, Mohtashami E, Jamialahmadi T, Afshari AR, Sahebkar A. Recent advances in glioblastoma multiforme therapy: A focus on autophagy regulation. Biomed Pharmacother 2022;155:113740. [PMID: 36166963 DOI: 10.1016/j.biopha.2022.113740] [Reference Citation Analysis]
3 Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD, Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F, Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh Z. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines (Basel) 2022;10:1448. [PMID: 36146527 DOI: 10.3390/vaccines10091448] [Reference Citation Analysis]
4 Qoorchi Moheb Seraj F, Heravi-Faz N, Soltani A, Ahmadi SS, Shahbeiki F, Talebpour A, Afshari AR, Ferns GA, Bahrami A. Thymol has anticancer effects in U-87 human malignant glioblastoma cells. Mol Biol Rep 2022. [PMID: 35997850 DOI: 10.1007/s11033-022-07867-3] [Reference Citation Analysis]
5 Wang X, Han M, Chen S, Sun Y, Tan R, Huang B. The copper-associated protein STEAP2 correlated with glioma prognosis and immune infiltration. Front Cell Neurosci 2022;16:944682. [DOI: 10.3389/fncel.2022.944682] [Reference Citation Analysis]
6 Zhang C, Liu H, Tan Y, Xu Y, Li Y, Tong S, Qiu S, Chen Q, Su Z, Tian D, Zhou W, Zhong C. MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. Front Immunol 2022;13:865020. [DOI: 10.3389/fimmu.2022.865020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Yang S, Han Y, Bao B, Hu C, Li Z. Boosting the anti-tumor performance of disulfiram against glioblastoma by using ultrasmall nanoparticles and HIF-1α inhibitor. Composites Part B: Engineering 2022;243:110117. [DOI: 10.1016/j.compositesb.2022.110117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu X, Chen Y, Geng D, Li H, Jiang T, Luo Z, Wang J, Pang Z, Zhang J. Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme. Membranes 2022;12:744. [DOI: 10.3390/membranes12080744] [Reference Citation Analysis]
9 Gao Z, Xu J, Fan Y, Qi Y, Wang S, Zhao S, Guo X, Xue H, Deng L, Zhao R, Sun C, Zhang P, Li G. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. J Exp Clin Cancer Res 2022;41:223. [PMID: 35836243 DOI: 10.1186/s13046-022-02431-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S. Molecular and Circulating Biomarkers in Patients with Glioblastoma. Int J Mol Sci 2022;23:7474. [PMID: 35806478 DOI: 10.3390/ijms23137474] [Reference Citation Analysis]
11 Maksoud S. The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. Mol Neurobiol 2022. [PMID: 35696013 DOI: 10.1007/s12035-022-02915-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Guo QL, Dai XL, Yin MY, Cheng HW, Qian HS, Wang H, Zhu DM, Wang XW. Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. Mil Med Res 2022;9:26. [PMID: 35676737 DOI: 10.1186/s40779-022-00386-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Shoaf ML, Desjardins A. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. Neurotherapeutics 2022. [PMID: 35674873 DOI: 10.1007/s13311-022-01256-1] [Reference Citation Analysis]
14 Gatto L, Franceschi E, Tosoni A, Nunno VD, Bartolini S, Brandes AA. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream? Immunotherapy 2022. [PMID: 35670093 DOI: 10.2217/imt-2021-0277] [Reference Citation Analysis]
15 El Kheir W, Marcos B, Virgilio N, Paquette B, Faucheux N, Lauzon M. Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics 2022;14:1189. [DOI: 10.3390/pharmaceutics14061189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liang R, Wu C, Liu S, Zhao W. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers. Drug Deliv 2022;29:1620-30. [PMID: 35612318 DOI: 10.1080/10717544.2022.2075986] [Reference Citation Analysis]
17 Smiley SB, Zarrinmayeh H, Das SK, Pollok KE, Vannier MW, Veronesi MC. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. Ther Deliv 2022. [PMID: 35615860 DOI: 10.4155/tde-2021-0086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yuan F, Cai X, Cong Z, Wang Y, Geng Y, Aili Y, Du C, Zhu J, Yang J, Tang C, Zhang A, Zhao S, Ma C. Roles of the m6A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol 2022;13:798583. [PMID: 35558067 DOI: 10.3389/fimmu.2022.798583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wang M, Chen B, Zhang W, Zhang F, Qiu Y, Lin Y, Yang S. Dematin inhibits glioblastoma malignancy through RhoA-mediated CDKs downregulation and cytoskeleton remodeling. Exp Cell Res 2022;:113196. [PMID: 35561787 DOI: 10.1016/j.yexcr.2022.113196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Carcelen M, Velasquez C, Vidal V, Gutiérrez O, Fernández-luna JL. Signaling Pathways Regulating the Expression of the Glioblastoma Invasion Factor TENM1. Biomedicines 2022;10:1104. [DOI: 10.3390/biomedicines10051104] [Reference Citation Analysis]
21 Niedbała M, Malarz K, Sharma G, Kramer-Marek G, Kaspera W. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. Onco Targets Ther 2022;15:437-68. [PMID: 35509452 DOI: 10.2147/OTT.S215997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gao W, Li Y, Zhang T, Lu J, Pan J, Qi Q, Dong S, Chen X, Su Z, Li J. Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma. J Inflamm Res 2022;15:2731-43. [PMID: 35509325 DOI: 10.2147/JIR.S357787] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Schmitt RR, Mahajan SD, Pliss A, Prasad PN. Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy. Nanomedicine 2022;41:102513. [PMID: 34954380 DOI: 10.1016/j.nano.2021.102513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Colapietro A, Yang P, Rossetti A, Mancini A, Vitale F, Chakraborty S, Martellucci S, Marampon F, Mattei V, Gravina GL, Iorio R, Newman RA, Festuccia C. The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma. Front Pharmacol 2022;13:852941. [DOI: 10.3389/fphar.2022.852941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Cheng W, Su YL, Hsu HH, Lin YH, Chu LA, Huang WC, Lu YJ, Chiang CS, Hu SH. Rabies Virus Glycoprotein-Mediated Transportation and T Cell Infiltration to Brain Tumor by Magnetoelectric Gold Yarnballs. ACS Nano 2022;16:4014-27. [PMID: 35225594 DOI: 10.1021/acsnano.1c09601] [Reference Citation Analysis]
26 Ma S, Guo Z, Wang B, Yang M, Yuan X, Ji B, Wu Y, Chen S. A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them. Front Genet 2022;12:832627. [DOI: 10.3389/fgene.2021.832627] [Reference Citation Analysis]
27 Li J, Bi, Zhang X, Cao Y, Lv K, Jiang L. Network Pharmacology and Inflammatory Microenvironment Strategy Approach to Finding the Potential Target of Siraitia grosvenorii (Luo Han Guo) for Glioblastoma. Front Genet 2021;12:799799. [PMID: 34987553 DOI: 10.3389/fgene.2021.799799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jenseit A, Camgöz A, Pfister SM, Kool M. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. Acta Neuropathol 2022;143:1-13. [PMID: 34762160 DOI: 10.1007/s00401-021-02382-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Long C, Yuan L, Wei W, Li J. Overcoming chemoresistance in glioblastoma by fluvastatin via prenylation-dependent inhibition of Ras signaling. Hum Exp Toxicol 2022;41:9603271221125934. [PMID: 36171180 DOI: 10.1177/09603271221125934] [Reference Citation Analysis]
30 Xiao T, He M, Xu F, Fan Y, Jia B, Shen M, Wang H, Shi X. Macrophage Membrane-Camouflaged Responsive Polymer Nanogels Enable Magnetic Resonance Imaging-Guided Chemotherapy/Chemodynamic Therapy of Orthotopic Glioma. ACS Nano 2021;15:20377-90. [PMID: 34860014 DOI: 10.1021/acsnano.1c08689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
31 Zhao J, Zhang W, Wu T, Wang H, Mao J, Liu J, Zhou Z, Lin X, Yan H, Wang Q. Efferocytosis in the Central Nervous System. Front Cell Dev Biol 2021;9:773344. [PMID: 34926460 DOI: 10.3389/fcell.2021.773344] [Reference Citation Analysis]
32 Giambra M, Messuti E, Di Cristofori A, Cavandoli C, Bruno R, Buonanno R, Marzorati M, Zambuto M, Rodriguez-Menendez V, Redaelli S, Giussani C, Bentivegna A. Characterizing the Genomic Profile in High-Grade Gliomas: From Tumor Core to Peritumoral Brain Zone, Passing through Glioma-Derived Tumorspheres. Biology (Basel) 2021;10:1157. [PMID: 34827152 DOI: 10.3390/biology10111157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Liang F, Zhu L, Wang C, Yang Y, He Z. BSA-MnO2-SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy. RSC Adv 2021;11:35331-41. [PMID: 35493189 DOI: 10.1039/d1ra06705b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Torrisi F, Alberghina C, Lo Furno D, Zappalà A, Valable S, Li Volti G, Tibullo D, Vicario N, Parenti R. Connexin 43 and Sonic Hedgehog Pathway Interplay in Glioblastoma Cell Proliferation and Migration. Biology (Basel) 2021;10:767. [PMID: 34439999 DOI: 10.3390/biology10080767] [Cited by in F6Publishing: 9] [Reference Citation Analysis]